3ZHANG L, RAMRATNAM B, TENNER- RACZ K, et al. Quantifying residual HIV- 1 replication in patients receiving combination antiretroviral therapy[J]. N Engl J Med, 1999, 340 (21) : 1605-1613.
4Union Nation AIDS. 2012 China AIDS response progress report [EB/OL]. (2012-03-31)[2013-08-10]. http://www.unaids.org/ en / dataanalysis / knowyourresponse / countryprogressreports / 2012 countries/ce CN Narrative_Report[1].pdf.
5POMMIER Y, JOHNSON AA, MAREHAND C. Integrase inhibitors to treat HIV/AIDS[J]. Nat Rev Drug Discov, 2005, 4 (3) : 236-248.
6U.S. Food and Drug Administration. FDA approval of isentress (raltegravir)[EB/OL]. (2010-10-12) [2013-08-15]. http://www. fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVand AIDSActivities/ucm 124040.htm.
7OPAR A. New HIV drug classes on the horizon[J]. Nat Rev Drug Diseov, 2007, 6(4): 258-259.
8ERON JJ, COOPER DA, STEIGBIGEL RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo- controlled triMs[J]. Lancet Infect Dis, 2013, 13(7): 587-596.
10ELION R, MOLINA JM, ARRIBAS JR, et al. Efficacy and safety results from a randomized, double blind, active controlled trial of elvitegravir (once-daily) versus rahegravir (twice-daily) in treatment-experienced HIV-positive patients: long term 96- week data[EB/OL]. [2014-01-06]. http://iasociety.org/Abstracts/ A200744511.aspx.
